A new trading day began on Friday, with Corvus Pharmaceuticals Inc (NASDAQ: CRVS) stock price up 7.50% from the previous day of trading, before settling in for the closing price of $5.73. CRVS’s price has ranged from $2.54 to $10.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 8.47% over the past five years. Meanwhile, its annual earnings per share averaged 63.24%. With a float of $54.39 million, this company’s outstanding shares have now reached $74.51 million.
Corvus Pharmaceuticals Inc (CRVS) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Corvus Pharmaceuticals Inc is 27.01%, while institutional ownership is 36.89%. The most recent insider transaction that took place on Jun 27 ’25, was worth 4,891,894. In this transaction Director of this company sold 1,176,332 shares at a rate of $4.16, taking the stock ownership to the 7,165,006 shares. Before that another transaction happened on Jun 27 ’25, when Company’s Director sold 1,176,332 for $4.16, making the entire transaction worth $4,891,894. This insider now owns 7,165,006 shares in total.
Corvus Pharmaceuticals Inc (CRVS) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.6 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 63.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.52% during the next five years compared to 8.47% growth over the previous five years of trading.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Trading Performance Indicators
Here are Corvus Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.02, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.59 in one year’s time.
Technical Analysis of Corvus Pharmaceuticals Inc (CRVS)
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) saw its 5-day average volume 0.7 million, a negative change from its year-to-date volume of 0.79 million. As of the previous 9 days, the stock’s Stochastic %D was 73.21%.
During the past 100 days, Corvus Pharmaceuticals Inc’s (CRVS) raw stochastic average was set at 99.69%, which indicates a significant increase from 99.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.33 in the past 14 days, which was higher than the 0.27 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.66, while its 200-day Moving Average is $4.78. Nevertheless, the first resistance level for the watch stands at $6.31 in the near term. At $6.45, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.74. If the price goes on to break the first support level at $5.88, it is likely to go to the next support level at $5.59. The third support level lies at $5.45 if the price breaches the second support level.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Key Stats
With a market capitalization of 459.01 million, the company has a total of 74,514K Shares Outstanding. Currently, annual sales are 0 K while annual income is -62,290 K. The company’s previous quarter sales were 0 K while its latest quarter income was -8,000 K.
